The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma

Blood

Volumn 102, Issue 10, 2003, Pages 3737-3742

  Borchmann, Peter ^a   Treml, John F ^b   Hansen, Hinrich ^b   Gottstein, Claudia ^b   Schnell, Roland ^b   Staak, Oliver ^b   Zhang, Hui Fen ^b   Davis, Thomas ^b   Keler, Tibor ^b   Diehl, Volker ^b   Graziano, Robert F ^b   Engert, Andreas ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5F11; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DOSE RESPONSE; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

EID: 0242579150     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-02-0515     Document Type: Article

References (36)

1. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881-895.
2. Bonadonna G, Santoro A, Bonfante V, Valagussa P. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. Cancer Treat Rep. 1982;66:881-887.
3. Kaplan HS. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer. 1980;45:2439-2474.
4. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998;16:3810-3821.
5. Carella AM. Indications for autologous bone marrow transplantation in Hodgkin's disease. Leuk Lymphoma. 1992;7(suppl):21-22.
6. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol. 2000;18:332-339.
7. Kanzler H, Hansmann ML, Kapp U, et al. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood. 1996;87:3429-3436.
8. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325:1525-1533.
9. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299:65-67.
10. Horn-Lohrens O, Tiemann M, Lange H, et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer. 1995;60:539-544.
11. Engert A, Burrows F, Jung W, et al. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res. 1990;50:84-88.
12. Schnell R, Linnartz C, Katouzi AA, et al. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer. 1995;63:238-244.
13. Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999;163:194-205.
14. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157-164.
15. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol. 1996;157:3635-3639.
16. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10:457-470.
17. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112:241-247.
18. Leroy X, Augusto D, Leteurtre E, Gosselin B. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem. 2002;50:283-285.
19. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
20. Ralfkiaer E, Bosq J, Gatter KC, et al. Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res. 1987;279:285-292.
21. Hsu SM, Ho YS, Hsu PL. Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells. J Natl Cancer Inst. 1987;79:1091-1099.
22. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002;62:3736-3742.
23. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer. 2001;85:1619-1623.
24. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998;95:427-436.
25. Colffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
26. Horie R, Watanabe T, Morishita Y, et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene. 2002;21:2493-2503.
27. Vinante F, Rigo A, Scupoli MT, Pizzolo G. CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. Blood. 2002;99:52-60.
28. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96:4307-4312.
29. Stein H, Gerdes J, Schwab U, et al. Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol Oncol. 1983;1:21-29.
30. Falini B, Flenghi L, Fedeli L, et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol. 1992;82:38-45.
31. Franke AC, Jung D, Ellis TM. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. Hybridoma. 2000;19:43-48.
32. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83:2045-2056.
33. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953.
34. Pullen SS, Labadia ME, Ingraham RH, et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry. 1999;38:10168-10177.
35. Horie R, Watanabe T, Ito K, et al. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol. 2002;160:1647-1654.
36. Matsuno H, Yudoh K, Nakazawa F, et al. Anti-rheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol. 2002;29:1609-1614.